450 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Kelly Lawrence W & Associates Inc. CA

Kelly Lawrence W & Associates Inc. CA bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, HoldingsChannel.com reports. The firm bought 450 shares of the company’s stock, valued at approximately $39,000.

Several other institutional investors have also recently bought and sold shares of NVO. GQG Partners LLC increased its position in Novo Nordisk A/S by 74.7% during the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock worth $1,117,790,000 after purchasing an additional 5,556,460 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Novo Nordisk A/S by 34.2% during the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after buying an additional 2,947,771 shares during the last quarter. Folketrygdfondet lifted its stake in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Folketrygdfondet now owns 8,903,938 shares of the company’s stock valued at $765,917,000 after acquiring an additional 40,313 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Novo Nordisk A/S by 1.5% in the 4th quarter. Renaissance Technologies LLC now owns 8,312,996 shares of the company’s stock valued at $715,084,000 after acquiring an additional 123,681 shares during the last quarter. Finally, Sustainable Growth Advisers LP grew its position in Novo Nordisk A/S by 23.6% during the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock worth $459,416,000 after acquiring an additional 1,021,498 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. BMO Capital Markets reiterated a “market perform” rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday. Finally, BNP Paribas assumed coverage on Novo Nordisk A/S in a report on Tuesday. They issued an “underperform” rating for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $135.00.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $57.99 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a fifty day simple moving average of $75.52 and a 200 day simple moving average of $91.54. Novo Nordisk A/S has a twelve month low of $57.28 and a twelve month high of $148.15. The company has a market capitalization of $260.23 billion, a PE ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S’s payout ratio is 49.54%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.